Richard Nolan Townsend - Jul 10, 2024 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Youjin Choi, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Jul 10, 2024
Transactions value $
-$911,738
Form type
4
Date filed
7/12/2024, 04:55 PM
Previous filing
Jun 12, 2024
Next filing
Aug 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Options Exercise $11.7K +5K +2.93% $2.33 176K Jul 10, 2024 Direct F1
transaction LXEO Common Stock Sale -$389K -23.6K -13.44% $16.45 152K Jul 10, 2024 Direct F1, F2
transaction LXEO Common Stock Sale -$56.4K -3.35K -2.2% $16.85 149K Jul 10, 2024 Direct F1, F3
transaction LXEO Common Stock Sale -$477K -27.9K -18.78% $17.06 121K Jul 11, 2024 Direct F1, F4
transaction LXEO Common Stock Sale -$1.91K -100 -0.08% $19.06 121K Jul 11, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Stock Option (right to buy) Options Exercise $0 -5K -3.48% $0.00 139K Jul 10, 2024 Common Stock 5K $2.33 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $15.83 to $16.825. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $16.83 to $16.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $16.7476 to $17.4703. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F6 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.